Rapid improvement of Clinical Disease Activity Index (CDAI) at 3 months predicts a preferable CDAI outcome at 1 year in active rheumatoid arthritis patients treated with tocilizumab: results from an observational investigation of daily clinical practice.
Kawashiri SY, Nishino A, Suzuki T, Nakashima Y, Horai Y, Ueki Y, Aramaki T, Fujikawa K, Nakashima M, Okada A, Migita K, Mizokami A, Matsuoka N, Mine M, Sakito S, Iwamoto N, Ichinose K, Tamai M, Nakamura H, Origuchi T, Aoyagi K, Eguchi K, Kawakami A.
Kawashiri SY, et al. Among authors: origuchi t.
Clin Exp Rheumatol. 2016 Sep-Oct;34(5):808-812. Epub 2016 Jun 22.
Clin Exp Rheumatol. 2016.
PMID: 27384149